Fulgent Genetics, Inc. (FLGT) — SEC Filings
Fulgent Genetics, Inc. (FLGT) — 17 SEC filings. Latest: 8-K (Dec 22, 2025). Includes 6 10-Q, 4 8-K, 2 DEFA14A.
View Fulgent Genetics, Inc. on SEC EDGAR
Overview
Fulgent Genetics, Inc. (FLGT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 7, 2025: Fulgent Genetics, Inc. (FLGT) reported a significant increase in revenue for the three months ended September 30, 2025, reaching $84.069 million, up from $71.743 million in the prior year, representing a 17.18% increase. For the nine months ended September 30, 2025, revenue grew to $239.335 million
Sentiment Summary
Across 17 filings, the sentiment breakdown is: 1 bearish, 15 neutral, 1 mixed. The dominant filing sentiment for Fulgent Genetics, Inc. is neutral.
Filing Type Overview
Fulgent Genetics, Inc. (FLGT) has filed 4 8-K, 6 10-Q, 2 DEFA14A, 1 DEF 14A, 2 10-K, 1 SC 13D/A, 1 SC 13G/A with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (17)
Risk Profile
Risk Assessment: Of FLGT's 15 recent filings, 1 were flagged as high-risk, 7 as medium-risk, and 7 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $84.069M |
| Net Income | ($6.608M) |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $117.641M |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Ming Hsieh
- Scott M. Stanton, Esq.
- Melanie Ruthrauff Levy, Esq.
Industry Context
Fulgent Genetics operates in the rapidly evolving fields of genetic diagnostics and precision medicine. The industry is characterized by significant technological advancements, increasing demand for personalized healthcare solutions, and a complex regulatory environment. Competition is intense, with players ranging from established diagnostic companies to emerging biotech firms focused on therapeutic development.
Top Tags
10-Q (4) · financials (4) · corporate-governance (3) · proxy-statement (3) · Biotechnology (2) · Therapeutic Development (2) · Medical Laboratories (2) · shareholder-vote (2) · 10-K (2) · healthcare (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Revenue | $84.069M | Increased 17.18% for Q3 2025 compared to Q3 2024 |
| Net Loss Attributable to Fulgent | ($6.608M) | Improved from ($14.648M) in Q3 2024 |
| Cash and Cash Equivalents | $117.641M | Increased from $55.144M at December 31, 2024 |
| Net Cash Used in Operating Activities | ($23.495M) | Increased from ($3.958M) for the nine months ended September 30, 2024 |
| Contingent Consideration | $5.731M | Fair value of shares for ANP Technologies acquisition |
| Outstanding Shares | 30,912,392 | As of November 3, 2025 |
| COVID-19 related revenue | $0.00 | Indicates a significant decline from previous periods, driving the overall revenue decrease. |
| Fiscal Year End | 2024-12-31 | The proxy statement covers the fiscal year ending on this date. |
| Filing Date | 20250326 | The date the Definitive Additional Materials were filed with the SEC. |
| Reporting Period End Date | 2024-09-30 | Indicates the end of the fiscal quarter for which financial information is reported. |
| Reporting Period Start Date | 2024-07-01 | Indicates the beginning of the fiscal quarter for which financial information is reported. |
| Quarterly Period | Q1 2024 | Reporting period |
| Previous Year End Date | 2023-12-31 | Financial statement date |
| Business Street Address | 4399 Santa Anita Ave | Primary location of Fulgent Genetics, Inc. |
| Business ZIP Code | 91731 | ZIP code for the company's business address |
Frequently Asked Questions
What are the latest SEC filings for Fulgent Genetics, Inc. (FLGT)?
Fulgent Genetics, Inc. has 17 recent SEC filings from Jan 2024 to Dec 2025, including 6 10-Q, 4 8-K, 2 DEFA14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of FLGT filings?
Across 17 filings, the sentiment breakdown is: 1 bearish, 15 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Fulgent Genetics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Fulgent Genetics, Inc. (FLGT) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Fulgent Genetics, Inc.?
Key financial highlights from Fulgent Genetics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for FLGT?
The investment thesis for FLGT includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Fulgent Genetics, Inc.?
Key executives identified across Fulgent Genetics, Inc.'s filings include Ming Hsieh, Scott M. Stanton, Esq., Melanie Ruthrauff Levy, Esq..
What are the main risk factors for Fulgent Genetics, Inc. stock?
Of FLGT's 15 assessed filings, 1 were flagged high-risk, 7 medium-risk, and 7 low-risk.
What are recent predictions and forward guidance from Fulgent Genetics, Inc.?
Forward guidance and predictions for Fulgent Genetics, Inc. are extracted from SEC filings as they are enriched.